Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Annals of Neurology Année : 2018

Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia

David Bergeron (1, 2) , Maria L Gorno-Tempini (3) , Gil D Rabinovici (3) , Miguel A Santos-Santos (3, 4) , William Seeley (3) , Bruce L Miller (3) , Yolande Pijnenburg (2) , M Antoinette Keulen (2) , Colin Groot (2) , Bart N.M. van Berckel (5) , Wiesje M van Der Flier (2) , Philip Scheltens (2) , Jonathan D Rohrer (6) , Jason D Warren (6) , Jonathan M Schott (6) , Nick C Fox (6) , Raquel Sánchez-Valle (7) , Oriol Grau-Rivera (7) , Ellen Gelpi (7, 8) , Harro Seelaar (9) , Janne M Papma (9) , John C van Swieten (9) , John R Hodges (10, 11, 12) , Cristian E Leyton (13, 14) , Olivier Piguet (10, 11, 12) , Emily J Rogalski (15, 16) , Marsel M Mesulam (16) , Lejla Koric (17) , Kristensen Nora (17) , Jeéreémie Pariente (18) , Bradford Dickerson (13, 14) , Ian R Mackenzie (19) , Ging-Yuek R Hsiung (19) , Serge Belliard (19) , David J Irwin (20) , David A Wolk (20) , Murray Grossman (20) , Matthew Jones (21, 22) , Jennifer Harris (22) , David Mann (22) , Julie S Snowden (22) , Patricio Chrem-Mendez (23) , Ismael L Calandri (23) , Alejandra A Amengual (23) , Carole Miguet-Alfonsi (24) , Eloi Magnin (24) , Giuseppe Magnani (25, 26) , Roberto Santangelo (25, 26) , Vincent Deramecourt (27) , Florence Pasquier (27) , Niklas Mattsson (28) , Christer Nilsson (28) , Oskar Hansson (28, 29) , Julia Keith (30) , Mario Masellis (31, 30) , Sandra E Black (31, 30) , Jordi A Matías-Guiu (32, 33) , María-Nieves Cabrera-Martin (32, 33) , Claire Paquet (34) , Julien Dumurgier (34) , Marc Teichmann (35) , Marie Sarazin (36) , Michel Bottlaender (36) , Bruno Dubois (37) , Christopher C. Rowe (38, 39) , Victor L. Villemagne (38, 39) , Rik Vandenberghe (40) , Elias Granadillo (41, 42) , Edmond Teng (41) , Mario Mendez (43) , Philipp T Meyer (44) , Lars Frings (44) , Alberto Lleó (45, 46, 47) , Rafael Blesa (45, 46) , Juan Fortea (45, 46) , Sang Won Seo (48) , Janine Diehl-Schmid (49) , Timo Grimmer (49) , Kristian Steen Frederiksen (50) , Pascual Sánchez-Juan (51) , Gaël Chételat (52) , Willemijn Jansen (53, 54) , Rémi W Bouchard (1) , Robert Jr Laforce (1, 55) , Pieter Jelle Visser (4, 53) , Rik Ossenkoppele (56, 28)
1 Interdisciplinary Clinic of Memory of the Child Jesus
2 Alzheimer Center Amsterdam
3 Memory and Aging Center [San Francisco, CA, États-Unis]
4 Llobregat Hospital [Barcelona]
5 VU University Medical Center [Amsterdam]
6 Institute of Neurology [London]
7 August Pi i Sunyer Biomedical Research Institute [Barcelona]
8 Medizinische Universität Wien = Medical University of Vienna
9 Erasmus MC - Erasmus University Medical Center [Rotterdam]
10 The University of Sydney
11 UNSW - University of New South Wales [Sydney]
12 Australian Research Council Centre of Excellence in Cognition and its Disorders [Sidney]
13 Massachusetts Alzheimer's Disease Research Center
14 HMS - Harvard Medical School [Boston]
15 Rush University [Chicago]
16 Northwestern University Medical School [Chicago]
17 Service de neurologie et de neuropsychologie
18 ToNIC - Toulouse NeuroImaging Center
19 UBC - University of British Columbia
20 University of Pennsylvania
21 Greater Manchester Neurosciences Centre
22 University of Manchester [Manchester]
23 Neurological Research Institute [Buenos Aires]
24 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
25 Vita Salute University [Milan]
26 IRCCS Ospedale San Raffaele [Milan, Italy]
27 TCDV - Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046
28 Skane University Hospital [Lund]
29 Skane University Hospital [Malmo]
30 University of Toronto
31 SRI - Sunnybrook Research Institute [Toronto]
32 UCM - Universidad Complutense de Madrid = Complutense University of Madrid [Madrid]
33 San Carlos Clinical Hospital [Madrid]
34 Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]
35 CHU Pitié-Salpêtrière [AP-HP]
36 IMIV - U1023 - ERL9218 - Imagerie Moléculaire in Vivo
37 Centre des Maladies Cognitives et Comportementales [Paris]
38 Austin Health
39 University of Melbourne
40 University Hospitals Leuven [Leuven]
41 UCLA - University of California [Los Angeles]
42 VA Greater Los Angeles Healthcare System
43 West Los Angeles VA Medical Center
44 University Hospital Freiburg
45 UAB - Universitat Autònoma de Barcelona = Autonomous University of Barcelona = Universidad Autónoma de Barcelona
46 Santa Cruz and Saint Paul Hospital [Barcelona]
47 Center for Biomedical Network Research on Neurodegenerative Diseases [Barcelona]
48 Samsung Medical Center Sungkyunkwan University School of Medicine
49 TUM - Technische Universität Munchen - Technical University Munich - Université Technique de Munich
50 Danish Dementia Research Center [Copenhagen]
51 Marqués de Valdecilla University Hospital [Santander]
52 PhIND - Physiopathologie et imagerie des troubles neurologiques
53 MUMC - School for Mental Health and Neuroscience - Alzheimer Center Limburg
54 Banner Alzheimer's Institute [Phoenix]
55 Clinique Interdisciplinaire de Mémoire de l'Enfant-Jésus
56 VU - Vrije Universiteit Amsterdam [Amsterdam]
Wiesje M van Der Flier
  • Fonction : Auteur
  • PersonId : 889956
Nick C Fox
  • Fonction : Auteur
  • PersonId : 893842
Harro Seelaar
  • Fonction : Auteur
  • PersonId : 889978
Serge Belliard
  • Fonction : Auteur
  • PersonId : 893165
Christer Nilsson
  • Fonction : Auteur
  • PersonId : 902894
Marie Sarazin
  • Fonction : Auteur
  • PersonId : 842303
Michel Bottlaender
  • Fonction : Auteur
  • PersonId : 949163
Rik Vandenberghe
  • Fonction : Auteur
  • PersonId : 921848

Résumé

Objective: To estimate the prevalence of amyloid positivity, defined by positron emission tomography (PET)/cerebrospinal fluid (CSF) biomarkers and/or neuropathological examination, in primary progressive aphasia (PPA) variants. Methods: We conducted a meta-analysis with individual participant data from 1,251 patients diagnosed with PPA (including logopenic [lvPPA, n = 443], nonfluent [nfvPPA, n = 333], semantic [svPPA, n = 401], and mixed/unclassifiable [n = 74] variants of PPA) from 36 centers, with a measure of amyloid-β pathology (CSF [n = 600], PET [n = 366], and/or autopsy [n = 378]) available. The estimated prevalence of amyloid positivity according to PPA variant, age, and apolipoprotein E (ApoE) ε4 status was determined using generalized estimating equation models. Results: Amyloid-β positivity was more prevalent in lvPPA (86%) than in nfvPPA (20%) or svPPA (16%; p < 0.001). Prevalence of amyloid-β positivity increased with age in nfvPPA (from 10% at age 50 years to 27% at age 80 years, p < 0.01) and svPPA (from 6% at age 50 years to 32% at age 80 years, p < 0.001), but not in lvPPA (p = 0.94). Across PPA variants, ApoE ε4 carriers were more often amyloid-β positive (58.0%) than noncarriers (35.0%, p < 0.001). Autopsy data revealed Alzheimer disease pathology as the most common pathologic diagnosis in lvPPA (76%), frontotemporal lobar degeneration-TDP-43 in svPPA (80%), and frontotemporal lobar degeneration-TDP-43/tau in nfvPPA (64%). Interpretation: This study shows that the current PPA classification system helps to predict underlying pathology across different cohorts and clinical settings, and suggests that age and ApoE genotype should be considered when interpreting amyloid-β biomarkers in PPA patients. Ann Neurol 2018;84:737-748.

Dates et versions

inserm-02749861 , version 1 (03-06-2020)

Identifiants

Citer

David Bergeron, Maria L Gorno-Tempini, Gil D Rabinovici, Miguel A Santos-Santos, William Seeley, et al.. Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84 (5), pp.729-740. ⟨10.1002/ana.25333⟩. ⟨inserm-02749861⟩
115 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More